TAKING LIPID SCIENCE AND MANAGEMENT OF GLUCOSE METABOLISM DIABETES, OBESITY AND CARDIOVASCULAR DISEASE TO THE NEXT LEVEL
Tersus Life Sciences LLC is focused on its vision to improve glucose metabolism and insulin sensitivity, and, reducing health risks associated with diabetes, obesity, and cardiovascular disease. Our cornerstone product, Provinal®, has created a new paradigm in glucose metabolism, diabetes, obesity, and cardiovascular disease management, positioned to address and benefit millions of affected people globally.
The efficacy and safety profile of Provinal® has been demonstrated through clinical trials and the consumption of millions of doses of Provinal®. Provinal® and C16:1n7 Palmitoleic Acid are supported by over 100 scientific publications and presentations and recommended for use by at-risk individuals by leading medical societies and institutions from around the world. Current clinical trials being conducted by Tersus Life Sciences intend to demonstrate the improvement of glucose metabolism and insulin sensitivity, diabetes, and obesity while reducing the persistent risk of cardiovascular disease.
FORWARD LOOKING STATEMENTS AND DISCLAIMER
Tersus Life Sciences website, presentations, and Investors Private Placement Memorandum contain forward-looking statements, such as those relating to the commercial potential of Provinal®, clinical and regulatory efforts and timelines potential regulatory and pricing guidelines, patent litigation, competitive product: launch, intellectual property infringement, and defense, cash flow, research and development and other statements and representations that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and support and successful accomplishment of milestones of achievement.
These statements involve known and unknown risks, uncertainties, and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only of the company’s presentations and offerings.
Tersus Life Sciences Private Placement Memorandum and investment offering can be furnished on a confidential basis for the information of the person to whom it will be provided and delivered on behalf of Tersus Life Sciences.
Prospective investors are invited to ask questions of the management team of Tersus Life Sciences concerning the terms and conditions of the investment and the Company’s offering and to obtain additional information necessary to verify the accuracy of any of the information contained in the Tersus Life Sciences Private Placement Memorandum. Prospective investors may request additional information by writing to Tersus Life Sciences, 8000 Health Center Blvd. Suite 100, Bonita Springs Florida 34135, emailing firstname.lastname@example.org or calling the management team at Tersus Life Sciences during normal business hours at 239-390-1226.